$1,000 – $3,000 Paid Clinical Trials
440 studies
Standard inpatient Phase 1 studies with multi-day residential stays typically compensate $1,000–$3,000.
Compensation amounts shown are typical ranges for this study type — not guaranteed amounts. Actual compensation is set by each study sponsor and documented in the informed consent form. ClinicalTrials.gov does not include a structured compensation field.
Showing 21–40 of 440 studies
Recruiting
Phase 1
A Study of NHL907 in Healthy Adult Participants
healthy adult participants
NeuHyll AUS Pty Ltd64 enrolled1 locationNCT07580924
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis
Healthy VolunteersSclerodermaSystemic Sclerosis (SSc)+1 more
Prolium Bioscience, Inc74 enrolled2 locationsNCT07641634
Recruiting
Phase 1
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
Healthy
Merck Sharp & Dohme LLC60 enrolled1 locationNCT07300280
Recruiting
Phase 1
Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ
Healthy Participants Study
First Affiliated Hospital of Zhejiang University104 enrolled1 locationNCT07640438
Recruiting
Phase 1
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
Healthy
Immunome, Inc.20 enrolled1 locationNCT07610005
Recruiting
Phase 1
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Healthy VolunteersOverweight or Obesity
Hoffmann-La Roche30 enrolled2 locationsNCT07499050
Recruiting
Phase 1
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Healthy Participants
Deciphera Pharmaceuticals, LLC24 enrolled1 locationNCT07539090
Recruiting
Phase 1
SAR447971 First-in-human Study
Healthy VolunteersHidradenitis
Sanofi114 enrolled1 locationNCT07629336
Recruiting
Phase 1
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
Healthy Subjects
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.40 enrolled1 locationNCT07241910
Recruiting
Phase 1
A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects
Healthy Adult
Dong-A ST Co., Ltd.12 enrolled1 locationNCT07633691
Recruiting
Phase 1
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
healthy adult participants
Astria Therapeutics, Inc.180 enrolled3 locationsNCT07635095
Recruiting
Phase 1
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Rheumatoid ArthritisHealthySystemic Lupus Erythematosus
Eli Lilly and Company63 enrolled1 locationNCT07276958
Recruiting
Phase 1
A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants
Healthy Participants Study
Shanghai Argo Biopharmaceutical Co., Ltd.24 enrolled1 locationNCT07577479
Recruiting
Phase 1
Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers
HealthyHealthy Smoker
Atisama Therapeutics90 enrolled1 locationNCT07285122
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 1
A Study of LY3867070 in Healthy Participants
Healthy
Eli Lilly and Company196 enrolled2 locationsNCT07021547
Recruiting
Phase 1
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
Healthy Volunteers (HV)
Jade Biosciences, Inc.40 enrolled1 locationNCT07525947
Recruiting
Phase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
HealthyAlzheimer Disease
Eli Lilly and Company128 enrolled13 locationsNCT06657768
Recruiting
Phase 1
A Study of LY4088044 in Healthy Participants
Healthy
Eli Lilly and Company104 enrolled6 locationsNCT07090785
Recruiting
Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Healthy Participants
Incyte Corporation24 enrolled1 locationNCT07588139